New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Endometriosis Drugs Industry" - https://www.reportlinker.com/p06051278/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year
Global Endometriosis Drugs Market to Reach $2.9 Billion by 2027
Amid the COVID-19 crisis, the global market for Endometriosis Drugs estimated at US$2.4 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at aCAGR of 2.8% over the period 2020-2027. Hormone therapy, one of the segments analyzed in the report, is projected to record 3.1% CAGR and reach US$1.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Analgesics segment is readjusted to a revised 2.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $710.9 Million, While China is Forecast to Grow at 2.6% CAGR
The Endometriosis Drugs market in the U.S. is estimated at US$710.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$524.6 Million by the year 2027 trailing a CAGR of 2.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 2.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.
Select Competitors (Total 38 Featured) -
AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG
Kissei Pharmaceutical Co. Ltd.
Neurocrine Biosciences Inc.
ObsEva SA
Pfizer Inc.
Repros Therapeutics Inc.
Takeda Pharmaceutical Company Limited
ValiRx plc
Read the full report: https://www.reportlinker.com/p06051278/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Endometriosis: An Introductory Prelude
Recent Market Activity
Endometriosis Facts in a Nutshell
Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet
Medical Needs
Key Endometriosis Drugs on the Market
The Pipeline Review
Key Endometriosis Drugs in the Pipeline: 2017
Endometriosis Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Astellas Pharma Inc. (Japan)
AstraZeneca Plc (UK)
Bayer AG (Germany)
Debiopharm Group (Switzerland)
Evotec AG (Germany)
Kissei Pharmaceutical Co., Ltd. (Japan)
Neurocrine Biosciences, Inc. (USA)
ObsEva SA (Switzerland)
Pfizer, Inc. (USA)
Repros Therapeutics, Inc. (USA)
Roivant Sciences GmbH (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
ValiRx plc (UK)
3. MARKET TRENDS & DRIVERS
Steady Growth Expected Over the Next Few Years
Emerging Treatment for Endometriosis & Endometrial Cancer
Global Awareness Campaigns and Efforts
Uptrend in Healthcare Expenditure Creates Substantial
Opportunities
Developed Regions Remain Primary Revenue Contributors
Developing Regions Exhibit Immense Growth Potential
Stable Economic Scenario to Augment Market Prospects
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Endometriosis Drugs Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2027
Table 2: World Recent Past, Current & Future Analysis for
Endometriosis Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 3: World Historic Review for Endometriosis Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 4: World 15-Year Perspective for Endometriosis Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027
Table 5: World Recent Past, Current & Future Analysis for
Hormone therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 6: World Historic Review for Hormone therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 7: World 15-Year Perspective for Hormone therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 8: World Recent Past, Current & Future Analysis for
Analgesics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 9: World Historic Review for Analgesics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 10: World 15-Year Perspective for Analgesics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 11: USA Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 12: USA Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 13: USA 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
CANADA
Table 14: Canada Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 15: Canada Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 16: Canada 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
JAPAN
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 17: Japan Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 18: Japan Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 19: Japan 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
CHINA
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 20: China Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 21: China Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 22: China 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
EUROPE
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 23: Europe Recent Past, Current & Future Analysis for
Endometriosis Drugs by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR
Table 24: Europe Historic Review for Endometriosis Drugs by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 25: Europe 15-Year Perspective for Endometriosis Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2021 & 2027
Table 26: Europe Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 27: Europe Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 28: Europe 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
FRANCE
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 29: France Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 30: France Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 31: France 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
GERMANY
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 32: Germany Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 33: Germany Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 34: Germany 15-Year Perspective for Endometriosis Drugs
by Product Type - Percentage Breakdown of Value Sales for
Hormone therapy and Analgesics for the Years 2012, 2021 & 2027
ITALY
Table 35: Italy Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 36: Italy Historic Review for Endometriosis Drugs by
Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 37: Italy 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
UNITED KINGDOM
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 38: UK Recent Past, Current & Future Analysis for
Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 39: UK Historic Review for Endometriosis Drugs by Product
Type - Hormone therapy and Analgesics Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 40: UK 15-Year Perspective for Endometriosis Drugs by
Product Type - Percentage Breakdown of Value Sales for Hormone
therapy and Analgesics for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 41: Rest of Europe Recent Past, Current & Future Analysis
for Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 42: Rest of Europe Historic Review for Endometriosis
Drugs by Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 43: Rest of Europe 15-Year Perspective for Endometriosis
Drugs by Product Type - Percentage Breakdown of Value Sales for
Hormone therapy and Analgesics for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Endometriosis Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 44: Asia-Pacific Recent Past, Current & Future Analysis
for Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 45: Asia-Pacific Historic Review for Endometriosis Drugs
by Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 46: Asia-Pacific 15-Year Perspective for Endometriosis
Drugs by Product Type - Percentage Breakdown of Value Sales for
Hormone therapy and Analgesics for the Years 2012, 2021 & 2027
REST OF WORLD
Table 47: Rest of World Recent Past, Current & Future Analysis
for Endometriosis Drugs by Product Type - Hormone therapy and
Analgesics - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 48: Rest of World Historic Review for Endometriosis Drugs
by Product Type - Hormone therapy and Analgesics Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 49: Rest of World 15-Year Perspective for Endometriosis
Drugs by Product Type - Percentage Breakdown of Value Sales for
Hormone therapy and Analgesics for the Years 2012, 2021 & 2027
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06051278/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
